NCT06527677 - Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 19, 2024

Primary Completion Date

July 3, 2025

Study Completion Date

July 10, 2025

Conditions

Renal Impairment

Interventions

DRUG

ANT3310

ANT3310 will be administered as a single intravenous infusion over 3 hours at a constant rate.

DRUG

Meropenem

meropenem will be administered as a single intravenous infusion over 3 hours at a constant rate.

Trial Locations (1)

CRS Clinical Research Services Kiel GmbH, Kiel